Skip to main content
Erschienen in: Tumor Biology 1/2014

01.01.2014 | Research Article

Genetic polymorphisms in XRCC1 gene and susceptibility to glioma in Chinese Han population

verfasst von: Zheng Jin, Haiyang Xu, Xianfeng Zhang, Gang Zhao

Erschienen in: Tumor Biology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Glioma is the most common type of primary brain malignancy in adults. The X-ray repair cross-complementing group 1 (XRCC1) is an important candidate gene for influencing the pathogenesis of glioma. This study aimed to evaluate the potential association between XRCC1 genetic polymorphisms and glioma susceptibility. This case–control study was conducted in Chinese Han populations consisting of 620 glioma cases and 630 cancer-free controls. XRCC1 genetic polymorphisms were detected by the polymerase chain reaction–restriction fragment length polymorphism and verified using DNA sequencing methods. The c.910A>G and c.1779C>G genetic polymorphisms were identified in this study. Our data suggested that the genotypes/alleles of these two genetic polymorphisms were statistically associated with the increased risk of glioma. As for c.910A>G, the risk of glioma for genotype GG was significantly higher than wild genotype AA (odds ratio (OR) = 1.98, 95 % confidence interval (CI) 1.33–2.94, P = 0.001). As for c.1779C>G, the genotype GG was statistically associated with the increased risk of glioma compared to wild genotype CC (OR = 1.80, 95 % CI 1.17–2.78, P = 0.007). Both of alleles G in c.910A>G and c.1779C>G may contribute to glioma susceptibility (G versus (vs.) A, OR = 1.30, 95 % CI 1.09–1.54, P = 0.003; G vs. C, OR = 1.19, 95 % CI 1.00–1.42, P = 0.045). Our findings indicate that the c.910A>G and c.1779C>G genetic polymorphisms are associated with the susceptibility to glioma in Chinese Han populations and might be used as molecular markers for evaluating glioma risk.
Literatur
2.
Zurück zum Zitat Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet. 2012;379:1984–96.PubMedCrossRef Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet. 2012;379:1984–96.PubMedCrossRef
3.
Zurück zum Zitat Wei X, Chen D, Lv T. A functional polymorphism in XRCC1 is associated with glioma risk: evidence from a meta-analysis. Mol Biol Rep. 2013;40:567–72.PubMedCrossRef Wei X, Chen D, Lv T. A functional polymorphism in XRCC1 is associated with glioma risk: evidence from a meta-analysis. Mol Biol Rep. 2013;40:567–72.PubMedCrossRef
4.
Zurück zum Zitat Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2:494–503. quiz 491 p following 516.PubMedCrossRef Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2:494–503. quiz 491 p following 516.PubMedCrossRef
5.
Zurück zum Zitat Tewari R, Choudhury SR, Mehta VS, Sen E. TNFalpha regulates the localization of CD40 in lipid rafts of glioma cells. Mol Biol Rep. 2012;39:8695–9.PubMedCrossRef Tewari R, Choudhury SR, Mehta VS, Sen E. TNFalpha regulates the localization of CD40 in lipid rafts of glioma cells. Mol Biol Rep. 2012;39:8695–9.PubMedCrossRef
6.
Zurück zum Zitat Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93–108.PubMedCrossRef Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93–108.PubMedCrossRef
7.
Zurück zum Zitat Zhang L, Wang Y, Qiu Z, Luo J, Zhou Z, Shu W. The XRCC1 Arg194Trp polymorphism is not a risk factor for glioma: a meta-analysis involving 1,440 cases and 2,562 controls. Exp Ther Med. 2012;4:1057–62.PubMedCentralPubMed Zhang L, Wang Y, Qiu Z, Luo J, Zhou Z, Shu W. The XRCC1 Arg194Trp polymorphism is not a risk factor for glioma: a meta-analysis involving 1,440 cases and 2,562 controls. Exp Ther Med. 2012;4:1057–62.PubMedCentralPubMed
8.
Zurück zum Zitat Melin B. Genetic causes of glioma: new leads in the labyrinth. Curr Opin Oncol. 2011;23:643–7.PubMedCrossRef Melin B. Genetic causes of glioma: new leads in the labyrinth. Curr Opin Oncol. 2011;23:643–7.PubMedCrossRef
9.
Zurück zum Zitat Liu Y, Scheurer ME, El-Zein R, Cao Y, Do KA, Gilbert M, et al. Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev. 2009;18:204–14.PubMedCentralPubMedCrossRef Liu Y, Scheurer ME, El-Zein R, Cao Y, Do KA, Gilbert M, et al. Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev. 2009;18:204–14.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Zhou LQ, Ma Z, Shi XF, Yin XL, Huang KX, Jiu ZS, et al. Polymorphisms of DNA repair gene XRCC1 and risk of glioma: a case–control study in Southern China. Asian Pac J Cancer Prev. 2011;12:2547–50.PubMed Zhou LQ, Ma Z, Shi XF, Yin XL, Huang KX, Jiu ZS, et al. Polymorphisms of DNA repair gene XRCC1 and risk of glioma: a case–control study in Southern China. Asian Pac J Cancer Prev. 2011;12:2547–50.PubMed
11.
Zurück zum Zitat Kiuru A, Lindholm C, Heinavaara S, Ilus T, Jokinen P, Haapasalo H, et al. XRCC1 and XRCC3 variants and risk of glioma and meningioma. J Neurooncol. 2008;88:135–42.PubMedCrossRef Kiuru A, Lindholm C, Heinavaara S, Ilus T, Jokinen P, Haapasalo H, et al. XRCC1 and XRCC3 variants and risk of glioma and meningioma. J Neurooncol. 2008;88:135–42.PubMedCrossRef
12.
Zurück zum Zitat Wang LE, Bondy ML, Shen H, El-Zein R, Aldape K, Cao Y, et al. Polymorphisms of DNA repair genes and risk of glioma. Cancer Res. 2004;64:5560–3.PubMedCrossRef Wang LE, Bondy ML, Shen H, El-Zein R, Aldape K, Cao Y, et al. Polymorphisms of DNA repair genes and risk of glioma. Cancer Res. 2004;64:5560–3.PubMedCrossRef
13.
Zurück zum Zitat Luo KQ, Mu SQ, Wu ZX, Shi YN, Peng JC. Polymorphisms in DNA repair genes and risk of glioma and meningioma. Asian Pac J Cancer Prev. 2013;14:449–52.PubMedCrossRef Luo KQ, Mu SQ, Wu ZX, Shi YN, Peng JC. Polymorphisms in DNA repair genes and risk of glioma and meningioma. Asian Pac J Cancer Prev. 2013;14:449–52.PubMedCrossRef
14.
Zurück zum Zitat Yosunkaya E, Kucukyuruk B, Onaran I, Gurel CB, Uzan M, Kanigur-Sultuybek G. Glioma risk associates with polymorphisms of DNA repair genes, XRCC1 and PARP1. Br J Neurosurg. 2010;24:561–5.PubMedCrossRef Yosunkaya E, Kucukyuruk B, Onaran I, Gurel CB, Uzan M, Kanigur-Sultuybek G. Glioma risk associates with polymorphisms of DNA repair genes, XRCC1 and PARP1. Br J Neurosurg. 2010;24:561–5.PubMedCrossRef
15.
Zurück zum Zitat Jiang L, Fang X, Bao Y, Zhou JY, Shen XY, Ding MH, et al. Association between the XRCC1 polymorphisms and glioma risk: a meta-analysis of case–control studies. PLoS One. 2013;8:e55597.PubMedCentralPubMedCrossRef Jiang L, Fang X, Bao Y, Zhou JY, Shen XY, Ding MH, et al. Association between the XRCC1 polymorphisms and glioma risk: a meta-analysis of case–control studies. PLoS One. 2013;8:e55597.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Mutamba JT, Svilar D, Prasongtanakij S, Wang XH, Lin YC, Dedon PC, et al. XRCC1 and base excision repair balance in response to nitric oxide. DNA Repair (Amst). 2011;10:1282–93.PubMedCentralPubMedCrossRef Mutamba JT, Svilar D, Prasongtanakij S, Wang XH, Lin YC, Dedon PC, et al. XRCC1 and base excision repair balance in response to nitric oxide. DNA Repair (Amst). 2011;10:1282–93.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Tudek B. Base excision repair modulation as a risk factor for human cancers. Mol Aspects Med. 2007;28:258–75.PubMedCrossRef Tudek B. Base excision repair modulation as a risk factor for human cancers. Mol Aspects Med. 2007;28:258–75.PubMedCrossRef
18.
Zurück zum Zitat Felini MJ, Olshan AF, Schroeder JC, North KE, Carozza SE, Kelsey KT, et al. DNA repair polymorphisms XRCC1 and MGMT and risk of adult gliomas. Neuroepidemiology. 2007;29:55–8.PubMedCrossRef Felini MJ, Olshan AF, Schroeder JC, North KE, Carozza SE, Kelsey KT, et al. DNA repair polymorphisms XRCC1 and MGMT and risk of adult gliomas. Neuroepidemiology. 2007;29:55–8.PubMedCrossRef
19.
Zurück zum Zitat Wang D, Hu Y, Gong H, Li J, Ren Y, Li G, et al. Genetic polymorphisms in the DNA repair gene XRCC1 and susceptibility to glioma in a Han population in northeastern China: a case–control study. Gene. 2012;509:223–7.PubMedCrossRef Wang D, Hu Y, Gong H, Li J, Ren Y, Li G, et al. Genetic polymorphisms in the DNA repair gene XRCC1 and susceptibility to glioma in a Han population in northeastern China: a case–control study. Gene. 2012;509:223–7.PubMedCrossRef
20.
21.
Zurück zum Zitat Hu XB, Feng Z, Fan YC, Xiong ZY, Huang QW. Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to glioma. Asian Pac J Cancer Prev. 2011;12:2981–4.PubMed Hu XB, Feng Z, Fan YC, Xiong ZY, Huang QW. Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to glioma. Asian Pac J Cancer Prev. 2011;12:2981–4.PubMed
22.
Zurück zum Zitat Liu HB, Peng YP, Dou CW, Su XL, Gao NK, Tian FM, et al. Comprehensive study on associations between nine SNPs and glioma risk. Asian Pac J Cancer Prev. 2012;13:4905–8.PubMedCrossRef Liu HB, Peng YP, Dou CW, Su XL, Gao NK, Tian FM, et al. Comprehensive study on associations between nine SNPs and glioma risk. Asian Pac J Cancer Prev. 2012;13:4905–8.PubMedCrossRef
23.
Zurück zum Zitat Rajaraman P, Hutchinson A, Wichner S, Black PM, Fine HA, Loeffler JS, et al. DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol. 2010;12:37–48.PubMedCentralPubMedCrossRef Rajaraman P, Hutchinson A, Wichner S, Black PM, Fine HA, Loeffler JS, et al. DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol. 2010;12:37–48.PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Jacobs DI, Bracken MB. Association between XRCC1 polymorphism 399 G→A and glioma among Caucasians: a systematic review and meta-analysis. BMC Med Genet. 2012;13:97.PubMedCentralPubMedCrossRef Jacobs DI, Bracken MB. Association between XRCC1 polymorphism 399 G→A and glioma among Caucasians: a systematic review and meta-analysis. BMC Med Genet. 2012;13:97.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Sun JY, Zhang CY, Zhang ZJ, Dong YF, Zhang AL, Wang ZW, et al. Association between XRCC1 gene polymorphisms and risk of glioma development: a meta-analysis. Asian Pac J Cancer Prev. 2012;13:4783–8.PubMedCrossRef Sun JY, Zhang CY, Zhang ZJ, Dong YF, Zhang AL, Wang ZW, et al. Association between XRCC1 gene polymorphisms and risk of glioma development: a meta-analysis. Asian Pac J Cancer Prev. 2012;13:4783–8.PubMedCrossRef
Metadaten
Titel
Genetic polymorphisms in XRCC1 gene and susceptibility to glioma in Chinese Han population
verfasst von
Zheng Jin
Haiyang Xu
Xianfeng Zhang
Gang Zhao
Publikationsdatum
01.01.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 1/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1050-2

Weitere Artikel der Ausgabe 1/2014

Tumor Biology 1/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.